Ana Paula Masson

Ana Paula Masson

Auto-generated profile, based on publicly available information

Ana Paula Masson

Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo 14049-900, Brazil

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2008 in BMC Immunology
Verified
Journal Article
Open access
PDF file
RRRogério S Rosada
Rogério S Rosada
Lucimara de la TorreLucimara de la Torre
Lucimara de la Torre
FFFabiani Frantz
Fabiani Frantz
ATAna Pf Trombone
Ana Pf Trombone
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
ACArlete Am Coelho-Castelo
Arlete Am Coelho-Castelo
Background: The greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.Results: We developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg).Conclusion: Our objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

30 September 2002 in Journal of Molecular Catalysis A: Chemical
Verified
Journal Article
Closed access
FVFábio S Vinhado
Fábio S Vinhado
PMPatrı́cia R Martins
Patrı́cia R Martins
AMAna P Masson
Ana P Masson
DADaniela G Abreu
Daniela G Abreu
EVEdnalva A Vidoto
Ednalva A Vidoto
YIYassuko Iamamoto
Yassuko Iamamoto

11 August 2008 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
PSPatrícia Rm Souza
Patrícia Rm Souza
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
JHJuliana Issa Hori
Juliana Issa Hori
SRSimone G. Ramos
Simone G. Ramos
DLDeison S Lima
Deison S Lima
CSCelio L Silva
Celio L Silva
Tuberculosis is a major threat to human health. The high disease burden remains unaffected and the appearance of extremely drug-resistant strains in different parts of the world argues in favor of the urgent need for a new effective vaccine. One of the promising candidates is heat-shock protein 65 when used as a genetic vaccine (DNAhsp65). Nonetheless, there are substantial data indicating that BCG, the only available anti-TB vaccine for clinical use, provides other important beneficial effects in immunized infants. We compared the protective efficacy of BCG and Hsp65 antigens in mice using different strategies: i) BCG, single dose subcutaneously; ii) naked DNAhsp65, four doses, intramuscularly; iii) liposomes containing DNAhsp65, single dose, intranasally; iv) microspheres containing DNAhsp65 or rHsp65, single dose, intramuscularly; and v) prime-boost with subcutaneous BCG and intramuscular DNAhsp65. All the immunization protocols were able to protect mice against infection, with special benefits provided by DNAhsp65 in liposomes and prime-boost strategies. Among the immunization protocols tested, liposomes containing DNAhsp65 represent the most promising strategy for the development of a new anti-TB vaccine.

16 May 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MEMilena Sobral Espíndola
Milena Sobral Espíndola
FFFabiani Frantz
Fabiani Frantz
LSLuana Silva Soares
Luana Silva Soares
AMAna Paula Masson
Ana Paula Masson
CTCristiane Tefé-Silva
Cristiane Tefé-Silva
LFLúcia H. Faccioli
Lúcia H. Faccioli
Schistosomiasis is one of the most important neglected diseases found in developing countries and affects 249 million people worldwide. The development of an efficient vaccination strategy is essential for the control of this disease. Previous work showed partial protection induced by DNA-Sm14 against Schistosoma mansoni infection, whereas DNA-Hsp65 showed immunostimulatory properties against infectious diseases, autoimmune diseases, cancer and antifibrotic properties in an egg-induced granuloma model.

1 August 2013 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
DCDyego Carlétti
Dyego Carlétti
DFDenise Morais da Fonseca
Denise Morais da Fonseca
AGAna Flávia Gembre
Ana Flávia Gembre
AMAna Paula Masson
Ana Paula Masson
LCLívia Weijenborg Campos
Lívia Weijenborg Campos
CHCynthia Horn
Cynthia Horn
Mycobacterium bovis BCG prime DNA ( Mycobacterium tuberculosis genes)-booster vaccinations have been shown to induce greater protection against tuberculosis (TB) than BCG alone. This heterologous prime-boost strategy is perhaps the most realistic vaccination for the future of TB infection control, especially in countries where TB is endemic. Moreover, a prime-boost regimen using biodegradable microspheres seems to be a promising immunization to stimulate a long-lasting immune response. The alanine proline antigen (Apa) is a highly immunogenic glycoprotein secreted by M. tuberculosis . This study investigated the immune protection of Apa DNA vaccine against intratracheal M. tuberculosis challenge in mice on the basis of a heterologous prime-boost regimen. BALB/c mice were subcutaneously primed with BCG and intramuscularly boosted with a single dose of plasmid carrying apa and 6,6′-trehalose dimycolate (TDM) adjuvant, coencapsulated in microspheres (BCG-APA), and were evaluated 30 and 70 days after challenge. This prime-boost strategy (BCG-APA) resulted in a significant reduction in the bacterial load in the lungs, thus leading to better preservation of the lung parenchyma, 70 days postinfection compared to BCG vaccinated mice. The profound effect of this heterologous prime-boost regimen in the experimental model supports its development as a feasible strategy for prevention of TB.

14 May 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
CZCarlos R. Zárate-Bladés
Carlos R. Zárate-Bladés
RRRodrigo F. Rodrigues
Rodrigo F. Rodrigues
PSPatricia R. M. Souza
Patricia R. M. Souza
WRWendy M. Rios
Wendy M. Rios
LSLuana S. Soares
Luana S. Soares
CSCelio L. Silva
Celio L. Silva
Despite the enormous efforts displayed globally in the fight against tuberculosis, the disease incidence has modified slightly, which has led to a renewed interest in immunotherapy. In general, successful immunotherapeutic candidates against tuberculosis are agents that can trigger strong, specific pro-inflammatory responses, especially of the T-helper (Th) 1 pattern. However, how these pro-inflammatory agents effectively kill the bacteria without eliciting immunopathology is not well understood. We reasoned that, in addition to the specific immune response elicited by immunotherapy, the evaluation of the overall pro-inflammatory responses should provide additional and valuable information that will be useful in avoiding immunopathology. We evaluated the overall IFN- and IL-17 pro-inflammatory responses among CD4(+), CD8(+) and T cells in the lungs of mice that were infected with M. tuberculosis and treated with a DNA vaccine in an immunotherapeutic regimen. Our results demonstrate that mice that effectively combat the pathogen develop a strong, specific Th1 immune response against the therapeutic antigen and have reduced lung inflammation, present in parallel a fine-tuning in the total IFN-- and IL-17-mediated immunity in the lungs. This modulation of the total immune response involves reducing the Th17 cell population, augmenting CD8(+) T cells that produce IFN- and increasing the total T cell frequency. These results stress the importance of a broad evaluation of not only the specific immune response at the time to evaluate new immune interventional strategies against tuberculosis but also non-conventional T cells, such as T lymphocytes.